KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) R&D In Process (2016 - 2017)

Historic R&D In Process for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Q3 2017 value amounting to $175.0 million.

  • Teva Pharmaceutical Industries' R&D In Process fell 3055.56% to $175.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $427.0 million, marking a year-over-year increase of 6297.71%. This contributed to the annual value of $23.0 million for FY2009, which is N/A changed from last year.
  • Teva Pharmaceutical Industries' R&D In Process amounted to $175.0 million in Q3 2017, which was down 3055.56% from $252.0 million recorded in Q3 2016.
  • In the past 5 years, Teva Pharmaceutical Industries' R&D In Process ranged from a high of $252.0 million in Q3 2016 and a low of $10.0 million during Q1 2016
  • For the 3-year period, Teva Pharmaceutical Industries' R&D In Process averaged around $115.2 million, with its median value being $99.5 million (2015).
  • The largest annual percentage gain for Teva Pharmaceutical Industries' R&D In Process in the last 5 years was 3055.56% (2017), contrasted with its biggest fall of 3055.56% (2017).
  • Teva Pharmaceutical Industries' R&D In Process (Quarter) stood at $24.0 million in 2015, then soared by 950.0% to $252.0 million in 2016, then crashed by 30.56% to $175.0 million in 2017.
  • Its R&D In Process stands at $175.0 million for Q3 2017, versus $252.0 million for Q3 2016 and $10.0 million for Q1 2016.